A share price of Elevation Oncology Inc [ELEV] is currently trading at $0.84, up 26.45%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ELEV shares have gain 41.43% over the last week, with a monthly amount glided 45.28%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Piper Sandler started tracking the stock with Overweight rating on May 31, 2024, and set its price target to $10. On May 14, 2024, Stephens initiated with a Overweight rating and assigned a price target of $8 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $7 on March 01, 2024. SVB Securities upgraded its rating to a Outperform and raised its price target to $8 on May 30, 2023. H.C. Wainwright started tracking with a Buy rating for this stock on December 23, 2021, and assigned it a price target of $12.
Elevation Oncology Inc experienced fluctuations in its stock price throughout the past year between $0.50 and $5.83. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Elevation Oncology Inc [NASDAQ: ELEV] shares were valued at $0.84 at the most recent close of the market. An investor can expect a potential return of 971.43% based on the average ELEV price forecast.
Analyzing the ELEV fundamentals
Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at -724.26%, Pretax Profit Margin comes in at -722.5%, and Net Profit Margin reading is -723.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.6 and Total Capital is -0.42. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.45.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7211 points at the first support level, and at 0.6029 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9465, and for the 2nd resistance point, it is at 1.0537.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Elevation Oncology Inc [NASDAQ:ELEV] is 17.77. Also, the Quick Ratio is 17.77, while the Cash Ratio stands at 8.13.
